GDTCHealthcare · BiotechnologyGDTC Stock Forecast: CytoMed Therapeutics Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 22 Aug 2026 — in the weakest quartile.
GDTC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores CytoMed Therapeutics Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
GDTC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GDTC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Oct 2024 | Benchmark | Reiterates | Speculative Buy | $5.00 |
| 11 June 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 4 Dec 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 21 July 2023 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GDTC appears on the weeks it earns a place.
GDTC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
CytoMed Therapeutics Ltd. (GDTC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 14.2×
- Price / book
- 2.4×
- EV / EBITDA
- −2.4×
Cheaper than 12% of US stocks
Cheaper than 42% of US stocks
Cheaper than 73% of US stocks
- Revenue growth (YoY)
- 46.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −535.3%
- Net margin
- 79.0%
Higher than 85% of US stocks
Higher than 7% of US stocks
Higher than 98% of US stocks
- Return on equity
- −50.3%
- Return on assets
- −29.3%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GDTC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CytoMed Therapeutics Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about GDTC stock
Is GDTC stock a buy right now?
Of the 1 analysts covering CytoMed Therapeutics Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytoMed Therapeutics Ltd. 17 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GDTC?
As at 22 Aug 2026, CytoMed Therapeutics Ltd. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
What is the GDTC stock forecast for 2030?
No analyst covering CytoMed Therapeutics Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GDTC are extrapolating price history, which says nothing about the business.
How has GDTC stock performed over the past year?
CytoMed Therapeutics Ltd. returned -42.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CytoMed Therapeutics Ltd. do?
Cytomed Therapeutics Ltd. is a biotechnology company dedicated to the research, development, and commercialization of novel medical therapies.
About CytoMed Therapeutics Ltd.
Cytomed Therapeutics Ltd. is a biotechnology company dedicated to the research, development, and commercialization of novel medical therapies. The company's primary focus is on creating innovative treatments for unmet medical needs, often targeting rare diseases and complex conditions with limited existing therapeutic options. By leveraging cutting-edge biotechnological techniques, Cytomed aims to advance healthcare solutions that improve patient outcomes and quality of life. This company operates at the intersection of life sciences and healthcare, making significant impacts in biotechnology and pharmaceutical sectors. It seeks collaborative partnerships with academic institutions, research organizations, and healthcare providers to accelerate its drug development pipeline and bring effective therapies to market. Cytomed Therapeutics Ltd. plays a crucial role in the biopharmaceutical industry by pushing the boundaries of medical science and contributing to the advancement of personalized medicine. In the financial markets, Cytomed represents a dynamic player within the biotechnology sector, attracting interest due to its potential for groundbreaking medical advancements. The company's progress in clinical trials and regulatory approvals can significantly influence its market position and investor perceptions.
CEO Dr. Wee Kiat Tan Ph.D. · 42 employees · Singapore · https://w2.cytomed.sg